Related Experiment Videos
Cyclocytidine chemotherapy for malignant melanoma
Cancer Treatment Reports
|March 1, 1978
Summary
Cyclocytidine chemotherapy showed a low response rate of 4% in patients with metastatic malignant melanoma. This treatment also presented unusual toxic effects, including delayed thrombocytopenia and hypotension.
Area of Science:
- Oncology
- Pharmacology
Background:
- Metastatic malignant melanoma is an advanced form of skin cancer with limited treatment options.
- Patients with advanced melanoma often receive extensive prior chemotherapy, impacting subsequent treatment efficacy.
Purpose of the Study:
- To evaluate the efficacy and toxicity of cyclocytidine in patients with metastatic malignant melanoma previously treated with chemotherapy.
Main Methods:
- A cohort of 29 patients with metastatic malignant melanoma received cyclocytidine at a dose of 240 mg/m2/day subcutaneously for 10 days.
- Patient response and adverse events were closely monitored.
Main Results:
- The overall response rate (complete plus partial remission) was low at 4%, with only one patient achieving a partial remission.
- Unusual toxic effects were observed, including delayed onset of thrombocytopenia, orthostatic hypotension, and jaw pain.
Conclusions:
- Cyclocytidine demonstrated limited efficacy as a salvage therapy for heavily pre-treated metastatic malignant melanoma patients.
- The observed unusual toxicities warrant further investigation and careful patient monitoring during cyclocytidine treatment.